Goldman Sachs Starts Ceres (CERE) at Neutral
Tweet Send to a FriendGet Alerts CERE Hot Sheet
Price: $2.31 +4.05%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 24
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 24
Trade CERE Now!
Goldman Sachs initiates coverage on recent IPO Ceres (NASDAQ: CERE) with a Neutral rating and $15 price target, suggesting 6% downside.
The firm views the company's leading position in sweet sorghum as a compelling growth opportunity. However, near term their view is balanced by the significant timing risk related to the adoption curve for sweet sorghum.
For an analyst ratings summary and ratings history on Ceres click here. For more ratings news on Ceres click here.
Shares of Ceres closed at $15.99 yesterday, with a 52 week range of $12.86-$18.70.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm views the company's leading position in sweet sorghum as a compelling growth opportunity. However, near term their view is balanced by the significant timing risk related to the adoption curve for sweet sorghum.
For an analyst ratings summary and ratings history on Ceres click here. For more ratings news on Ceres click here.
Shares of Ceres closed at $15.99 yesterday, with a 52 week range of $12.86-$18.70.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
- Goldman Sachs Resumes Coverage on Aetna (AET) at Buy
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

